ᐈ ReciBioPharm Boosts mRNA Therapy Manufacturing with Acuitas Partnership

📣 ReciBioPharm and Acuitas Therapeutics have expanded their partnership to provide tech transfer and manufacturing services for Acuitas’ lipid nanoparticle formulations for mRNA-based therapeutics and vaccines. ReciBioPharm will focus on advancing these therapies at its US Center of Excellence for Nucleic Acids in Watertown, MA. ReciBioPharm offers a comprehensive nucleic acid solution, including E. coli plasmid cell banks and LNP formulations. 🏭🔬

📢 ReciBioPharm Boosts mRNA Therapeutics with Acuitas Partnership

Introduction:

ReciBioPharm and Acuitas Therapeutics have announced a partnership to provide technology transfer and CGMP manufacturing for customers using Acuitas’ lipid nanoparticle (LNP) formulations for mRNA-based therapeutics and vaccines. This collaboration aims to accelerate the development and production of advanced therapeutics.

Main points:

ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, has partnered with Acuitas Therapeutics to provide technology transfer and CGMP manufacturing services for customers using Acuitas’ LNP formulations.
This partnership aims to support the rapid progression of advanced therapeutics from concept to clinic by leveraging Acuitas’ process and analytical expertise and ReciBioPharm’s flexible development capability and strong CGMP execution.
Ongoing work with Acuitas is being performed at ReciBioPharm’s U.S. Center of Excellence for Nucleic Acids, which includes a facility for process development and production suites.
ReciBioPharm offers a comprehensive nucleic acid solution at its Watertown site, including the production of plasmid cell banks, plasmid DNA, RNA drug substances, and LNP formulations with sterile fill-finish.
This partnership will enable the development and manufacturing of new mRNA-based therapeutics and vaccines for the benefit of patients.

Conclusion:

ReciBioPharm and Acuitas Therapeutics have expanded their partnership to provide technology transfer and CGMP manufacturing services for customers using Acuitas’ LNP formulations. This collaboration will accelerate the development and production of advanced therapeutics, including mRNA-based therapeutics and vaccines. By leveraging Acuitas’ expertise in process and analytical experience and ReciBioPharm’s flexible development capability and strong CGMP execution, this partnership aims to support the rapid progression of new therapies from concept to clinic. Overall, this collaboration will contribute to the advancement of the field of advanced therapeutics and benefit patients in need of innovative treatments.